Mehner Christine, Oberg Ann L, Goergen Krista M, Kalli Kimberly R, Maurer Matthew J, Nassar Aziza, Goode Ellen L, Keeney Gary L, Jatoi Aminah, Radisky Derek C, Radisky Evette S
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Genes Cancer. 2017 May;8(5-6):589-599. doi: 10.18632/genesandcancer.142.
Limited effectiveness of therapeutic agents targeting epidermal growth factor receptor (EGFR) in clinical trials using unselected ovarian cancer patients has prompted efforts to more effectively stratify patients who might best benefit from these therapies. A series of studies that have evaluated immunohistochemical (IHC) staining of EGFR in ovarian cancer biopsies has produced unclear results as to the utility of this measure as a prognostic biomarker. Here, we used one of the largest, single institution cohorts to date to determine possible associations of EGFR expression with patient outcome.
We performed IHC staining of EGFR in tissue microarrays including nearly 500 patient tumor samples. Staining was classified by subcellular localization (membranous, cytoplasmic) or by automated image analysis algorithms. We also performed a literature review to place these results in the context of previous studies.
No significant associations were found between EGFR subcellular localization or expression and histology, stage, grade, or outcome. These results were broadly consistent with the consensus of the reviewed literature.
These results suggest that IHC staining for EGFR may not be a useful prognostic biomarker for ovarian cancer patients. Future studies should pursue other staining methods or analysis in combination with other pathway mediators.
在未筛选的卵巢癌患者中进行的临床试验表明，针对表皮生长因子受体（EGFR）的治疗药物效果有限，这促使人们努力更有效地对可能从这些疗法中获益最大的患者进行分层。一系列评估卵巢癌活检组织中EGFR免疫组化（IHC）染色的研究，对于该检测作为预后生物标志物的实用性得出了不明确的结果。在此，我们使用了迄今为止最大的单机构队列之一，以确定EGFR表达与患者预后之间可能存在的关联。
我们对包含近500例患者肿瘤样本的组织芯片进行了EGFR的IHC染色。染色根据亚细胞定位（膜性、胞质）或通过自动图像分析算法进行分类。我们还进行了文献综述，以便将这些结果置于先前研究的背景中。
未发现EGFR亚细胞定位或表达与组织学、分期、分级或预后之间存在显著关联。这些结果与综述文献的共识大致一致。
这些结果表明，EGFR的IHC染色可能不是卵巢癌患者有用的预后生物标志物。未来的研究应探索其他染色方法或与其他信号通路介质结合进行分析。
